Home / Business and Economy / Novo Nordisk Wins Court Battle Over Semaglutide Spray
Novo Nordisk Wins Court Battle Over Semaglutide Spray
5 Aug
Summary
- Novo Nordisk secured a preliminary injunction in the Netherlands.
- The case involved a compounded semaglutide nasal spray.
- The court found Ceban infringed Novo Nordisk's semaglutide patent.
In a significant legal development, Novo Nordisk announced on Wednesday that it has successfully obtained a preliminary injunction in the Netherlands. The ruling came from a district court and is related to a patent infringement case involving a compounded semaglutide nasal spray. Semaglutide is the key active ingredient in Novo Nordisk's widely recognized weight-loss medication, Wegovy.
The Danish pharmaceutical company stated that the court concluded Ceban Ziekenhuisfarmacie had infringed upon Novo Nordisk's supplementary protection certificate (SPC) specifically covering semaglutide. This ruling mandates that the Dutch firm, Ceban, must immediately cease all infringing activities. Furthermore, the court has ordered Ceban to remove product listings and provide comprehensive disclosure of its supply chain information.
As part of the injunction, Ceban is also required to reimburse Novo Nordisk for its legal costs incurred during the proceedings. This legal victory underscores Novo Nordisk's commitment to protecting its intellectual property surrounding the semaglutide compound and its associated pharmaceutical products.
